Suwandinata FS, Bohle RM, Omwandho CA, Tinneberg HR, Gruessner SE.Management of vulvar melanoma and review of the literature.

A PROFOMWANDHOCHARLESO. "Suwandinata FS, Bohle RM, Omwandho CA, Tinneberg HR, Gruessner SE.Management of vulvar melanoma and review of the literature.". In: Eur J Gynaecol Oncol. 2007;28(3):220-4.; 2007.


Department of Obstetrics and Gynecology, Justus-Liebig-University of Giessen, Giessen, Germany. BACKGROUND: Vulvar melanoma represents a rare group of malignancies and is the second most common vulvar malignancy. Treatment options range from local excision of the tumor and sentinel lymph node dissection to radical resection involving en bloc vulvectomy and inguinofemoral lymphanedectomy. Vulvar melanomas have an overall poor prognosis, and there is lack of consensus in the published literature regarding treatment options. OBJECTIVE: To discuss the management of vulvar melanomas through review of the actual literature. METHODS: Identification of studies through computerized searches (January 2006) was conducted using MEDLINE (1966 to present), the Cochrane Central Register of Controlled Trials, the National Research Register and the Medical Research Council's Clinical Trials Register. The medical subject headings and text words used were: vulvar melanoma, malignant, management, case report, and therapy. The literature review was done over the past 36 years. RESULT: Results of these primary retrospective series have shown no improvement in the overall recovery or disease survival rates. CONCLUSION: Patients with malignant melanoma are often diagnosed at 70 years of age with multiple comorbidities. Less radical surgery presents a more realistic option for many patients without decreasing their survival rates. Surgery is still the gold standard of treatment and offers the best available treatment for controlling and potential curing of malignant melanomas. However, the whole concept of therapy should be tailored to meet the specific needs of individual patients.




UoN Websites Search